| Mach7 Technologies Limited (M7T) ORDINARY FULLY PAID |
Health Care |
$65 |
Quarterly Activities/Appendix 4C Cash Flow Report
|
30 Jan 2026 8:33AM |
$0.440 |
$0.275 |
fallen by
37.50%
|
|
M7T - Price-sensitive ASX Announcement
Full Release
Key Points
- Operating cashflow positive in Q2 FY26.
- Secured first Flamingo Architecture customer.
- Cash on hand A$18.5M, no debt.
- CARR of A$26.1M, ARR stable at A$23.0M.
- Progress in regulatory compliance with CE certification.
- Focus on platform capability and market presence.
- Cost savings through restructuring and optimizations.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Australian Strategic Materials Limited (ASM) ORDINARY FULLY PAID |
Materials |
$488 |
Quarterly Activities/Appendix 5B Cash Flow Report
|
30 Jan 2026 8:33AM |
$1.855 |
$1.795 |
fallen by
3.23%
|
|
ASM - Price-sensitive ASX Announcement
Full Release
Key Points
- ASM completed an institutional placement raising approximately A$55 million.
- Net cash from operating activities was negative A$4.021 million.
- End of quarter cash and cash equivalents stood at A$69.7 million.
- Major expenses included production and staff costs, and a loan repayment.
- ASM received government grants and tax incentives.
- Future plans include expansion and strategic partnerships.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| AdAlta Limited (1AD) ORDINARY FULLY PAID |
Health Care |
$13 |
Application for quotation of securities - 1AD
|
30 Jan 2026 8:32AM |
$0.005 |
$0.005 |
fallen by
0%
|
|
| Atlas Arteria (ALX) FPO STAP US PROHIBITED EXCLUDING QIB/QP |
Industrials |
$6,936 |
Q4 2025 Toll Revenue and Traffic Update
|
30 Jan 2026 8:32AM |
$4.910 |
$4.780 |
fallen by
2.65%
|
|
ALX - Price-sensitive ASX Announcement
Full Release
Key Points
- 9.5% increase in proportionate toll revenue for Q4 2025.
- Stable traffic with growth at Dulles Greenway and Chicago Skyway.
- Traffic impacted at Warnow Tunnel due to prior roadworks.
- Full-year 2025 traffic supported by growth in France.
- Toll revenue growth driven by toll increases and favorable forex rates.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Carnaby Resources Limited (CNB) ORDINARY FULLY PAID |
Materials |
$131 |
Quarterly Activities/Appendix 5B Cash Flow Report
|
30 Jan 2026 8:32AM |
$0.530 |
$0.475 |
fallen by
10.38%
|
|
CNB - Price-sensitive ASX Announcement
Full Release
Key Points
- Carnaby Resources Limited's quarterly update for 31 December 2025.
- Significant developments at Greater Duchess Copper Gold Project.
- Updated Mineral Resource Estimate with significant increases.
- Pre-Feasibility Study nearing completion, targeting production in H2 2026.
- High-grade assay results from Trekelano Prospect.
- Acquisition of remaining interest in Greater Duchess Joint Venture.
- Conducted $12.5 million placement to QIC Critical Minerals and Battery Technology Fund.
- Cash position at quarter end was $16.0 million.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Fat Prophets Global Contrarian Fund Limited (FPC) ORDINARY FULLY PAID |
Financials |
$42 |
Weekly NAV
|
30 Jan 2026 8:31AM |
$1.640 |
$1.480 |
fallen by
9.76%
|
|
| Ironbark Balanced Income Limited (IBC) ORDINARY FULLY PAID |
Financials |
$44 |
Update - Notification of buy-back - IBC
|
30 Jan 2026 8:31AM |
$0.440 |
$0.435 |
fallen by
1.14%
|
|
| L1 Long Short Fund Limited (LSF) ORDINARY FULLY PAID |
Financials |
$2,725 |
Net Tangible Asset Backing
|
30 Jan 2026 8:31AM |
$4.350 |
$4.300 |
fallen by
1.15%
|
|
| Nine Entertainment Co. Holdings Limited (NEC) ORDINARY FULLY PAID |
Communication Services |
$1,538 |
Nine accelerates strategic transformation
|
30 Jan 2026 8:31AM |
$1.090 |
$0.970 |
fallen by
11.01%
|
|
NEC - Price-sensitive ASX Announcement
Full Release
Key Points
- Nine acquires QMS Media for $850 million.
- Sale of radio assets to Laundy Family Office for $56 million.
- Conversion of NBN to an affiliate under WIN Network.
- Growth assets expected to contribute over 60% of revenue by FY27.
- Strategic focus on digital expansion and revenue diversification.
- Projected EPS accretive impact from strategic initiatives.
- Enhanced shareholder value and reduced broadcast exposure.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Nexus Minerals Limited (NXM) ORDINARY FULLY PAID |
Materials |
$34 |
Quarterly Activities/Appendix 5B Cash Flow Report
|
30 Jan 2026 8:30AM |
$0.073 |
$0.057 |
fallen by
21.92%
|
|
NXM - Price-sensitive ASX Announcement
Full Release
Key Points
- High-grade drilling results from Wallbrook Gold Project.
- Cash on hand at the end of the quarter is $7.8 million.
- Significant exploration progress in Crusader-Templar and other prospects.
- Discussions with potential operational and toll treatment partners are ongoing.
- Permitting and operational readiness for Crusader-Templar are advancing.
- Net cash outflow from operating activities is $1.73 million.
- Focus on systematic infill and extensional drilling.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Taiton Resources Limited (T88) ORDINARY FULLY PAID |
Materials |
$7 |
Quarterly Activities/Appendix 5B Cash Flow Report
|
30 Jan 2026 8:30AM |
$0.155 |
$0.060 |
fallen by
61.29%
|
|
T88 - Price-sensitive ASX Announcement
Full Release
Key Points
- E-PEPR applications approved by the Department for Energy and Mining, South Australia.
- Drilling completed at the Challenger West project.
- Drilling at Highway project scheduled for 1st quarter of 2026.
- Placement of new ordinary shares raised $2 million.
- Conversion of shareholder's loan to shares.
- Net cash from operating activities was a negative $338,000.
- Total cash and cash equivalents at quarter end were $629,000.
- Unused financing facilities of $1,000,000 available at quarter end.
- Capital raising involved issuing 33,408,000 new shares at $0.06 each.
- Appointment of Mr Shane Tomlinson as Executive Technical Director.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Orion Minerals Ltd (ORN) ORDINARY FULLY PAID |
Materials |
$247 |
Quarterly Cashflow Report
|
30 Jan 2026 8:29AM |
$0.034 |
$0.030 |
fallen by
11.76%
|
|
ORN - Price-sensitive ASX Announcement
Full Release
Key Points
- Net cash outflow from operating activities: $2.874 million.
- Exploration and evaluation expenses: $1.213 million.
- Financing activities generated: $9.110 million.
- Cash and cash equivalents at quarter end: $5.743 million.
- Estimated 1.41 quarters of funding available.
- Additional funding of ZAR23.6 million from IDC for Flat Mines.
- Glencore financing arrangements for US$200M - US$250M in progress.
- $A10M Early Funding Arrangement with Triple Flag for Prieska Mine.
- Report prepared according to ASX Listing Rules and Australian Accounting Standards.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Orion Minerals Ltd (ORN) ORDINARY FULLY PAID |
Materials |
$247 |
Quarterly Activities Report
|
30 Jan 2026 8:29AM |
$0.034 |
$0.030 |
fallen by
11.76%
|
|
ORN - Price-sensitive ASX Announcement
Full Release
Key Points
- Completion of due diligence for Glencore offtake and financing.
- Operational readiness and value engineering at Prieska Copper Zinc Mine.
- First concentrate from PCZM targeted by Christmas 2026.
- Exploration advancements at Okiep Copper Project.
- No safety incidents reported; high standards of environmental compliance maintained.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Enlitic Inc (ENL) CHESS DEPOSITARY INTERESTS 1:1 US PROHIBITED |
Health Care |
$10 |
Quarterly Activities/Appendix 4C Cash Flow Report
|
30 Jan 2026 8:29AM |
$0.014 |
$0.012 |
fallen by
14.29%
|
|
ENL - Price-sensitive ASX Announcement
Full Release
Key Points
- Record total contract value of A$4.3m in Q4 FY25.
- 16 new client agreements executed in Q4 FY25.
- Completed capital raise of A$2.6m; additional A$5.4m subject to approval.
- Net operating cash outflow of US$3.3m for the quarter.
- Cash balance of US$2.57m at the end of December 2025.
- Implemented cost reduction measures for US$2.5m in annual savings.
- Revenue impacted by expanded project scopes.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| NOVONIX Limited (NVX) ORDINARY FULLY PAID |
Information Technology |
$220 |
Application for quotation of securities - NVX
|
30 Jan 2026 8:29AM |
$0.390 |
$0.255 |
fallen by
34.62%
|
|
| Amplia Therapeutics Limited (ATX) ORDINARY FULLY PAID |
Health Care |
$67 |
Quarterly Activities/Appendix 4C Cash Flow Report
|
30 Jan 2026 8:28AM |
$0.130 |
$0.130 |
fallen by
0%
|
|
ATX - Price-sensitive ASX Announcement
Full Release
Key Points
- Amplia ended the December 2025 quarter with AUD 31.5 million in cash.
- Net operating cash inflows for the quarter were AUD 2.4 million.
- Received AUD 3.8 million from government grants and tax incentives.
- Operating outflows included AUD 0.9 million for staff and administration costs.
- ACCENT trial showed a 35% response rate with narmafotinib.
- AMPLICITY trial initiated to explore narmafotinib with FOLFIRINOX.
- Positive FDA feedback on dosage optimization for narmafotinib.
- Granted a key patent for narmafotinib.
- Listed on the US-based OTCQB Venture Market.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Origin Energy Limited (ORG) ORDINARY FULLY PAID |
Utilities |
$19,605 |
December 2025 Quarterly Report
|
30 Jan 2026 8:28AM |
$11.800 |
$11.380 |
fallen by
3.56%
|
|
| Helia Group Limited (HLI) ORDINARY FULLY PAID |
Financials |
$1,417 |
2025 Full Year Results Release Date
|
30 Jan 2026 8:28AM |
$5.780 |
$5.170 |
fallen by
10.55%
|
|
| RMA Global Limited (RMY) ORDINARY FULLY PAID |
Communication Services |
$27 |
Quarterly Activities/Appendix 4C Cash Flow Report
|
30 Jan 2026 8:28AM |
$0.049 |
$0.040 |
fallen by
18.37%
|
|
RMY - Price-sensitive ASX Announcement
Full Release
Key Points
- Net operating cash outflow of $592,000 in Q2 FY26.
- Cash receipts from customers totaled $5.8 million, an 11% increase from Q2 FY25.
- Organic cash receipts grew by 3%, excluding Curated Social.
- Operational cash payments increased by 25% compared to Q2 FY25.
- RMA Global Limited rebranded to Renowned.
- US subscription revenue rose by 38% year-on-year.
- ANZ revenue grew by 5% due to new multi-year partnerships.
- Cash on hand as of 31 December 2025 was $3.1 million.
- Focus on expanding US market with multi-year brokerage deals.
- Payments to related parties totaled $114,000, related to director fees.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Felix Gold Limited (FXG) ORDINARY FULLY PAID |
Materials |
$129 |
Quarterly Activities and Cashflow Reports
|
30 Jan 2026 8:28AM |
$0.385 |
$0.260 |
fallen by
32.47%
|
|
FXG - Price-sensitive ASX Announcement
Full Release
Key Points
- $18 million institutional placement completed
- Blair Way appointed as Non-Executive Director
- Significant expenditure on exploration and project studies in Alaska
- Targeting metal production in H2 2026
- Submitted applications for DOE pilot processing facility and exploration technology
- Strengthened executive and non-executive governance
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| NeuroScientific Biopharmaceuticals Ltd (NSB) ORDINARY FULLY PAID |
Health Care |
$33 |
Quarterly Activities/Appendix 4C Cash Flow Report
|
30 Jan 2026 8:27AM |
$0.135 |
$0.100 |
fallen by
25.93%
|
|
NSB - Price-sensitive ASX Announcement
Full Release
Key Points
- StemSmart™ Special Access Program for Crohn's Disease is advancing.
- Phase 2 Clinical Trial preparation is underway with real-world clinical data.
- Appointment of a Clinical & Scientific Advisory Board to support development.
- Technology transfer to Q-Gen for manufacturing readiness is progressing.
- Strong financial position with cash and cash equivalents approximately $6.4 million.
- Net cash outflow from operating activities was $532k for the quarter.
- Research and development payments totaled approximately $315k.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Lotus Resources Limited (LOT) ORDINARY FULLY PAID |
Energy |
$213 |
Quarterly Activities and Cash Flow Reports - December 2025
|
30 Jan 2026 8:27AM |
$0.225 |
$0.780 |
risen by
246.67%
|
|
LOT - Price-sensitive ASX Announcement
Full Release
Key Points
- Kayelekera Uranium Mine's production impacted by sulphuric acid supply issues.
- Production resumed mid-January with the best run time since restart.
- Acid plant rebuild on schedule for March 2026 commissioning.
- Uranium deliveries and strategy focus on market-linked pricing.
- Successful metallurgical testwork at Letlhakane could reduce acid consumption by 70%.
- Closing cash balance A$56.2M, exploring additional financing options.
- No Lost Time Injuries recorded, targeting two million LTI-free person days.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| ResMed Inc. (RMD) CDI 10:1 FOREIGN EXEMPT NYSE |
Health Care |
$16,116 |
Dividend/Distribution - RMD
|
30 Jan 2026 8:27AM |
$36.400 |
$28.560 |
fallen by
21.54%
|
|
| Regis Healthcare Limited (REG) ORDINARY FULLY PAID |
Health Care |
$1,920 |
Initial Director's Interest Notice
|
30 Jan 2026 8:27AM |
$6.610 |
$6.350 |
fallen by
3.93%
|
|
| Far Limited (FAR) ORDINARY FULLY PAID |
Energy |
$57 |
Quarterly Activities Report and Appendix 5B
|
30 Jan 2026 8:27AM |
$0.455 |
$0.618 |
risen by
35.71%
|
|
FAR - Price-sensitive ASX Announcement
Full Release
Key Points
- FAR Limited reported a cash balance of US$1.9 million at the end of the December 2025 quarter.
- The company entered into a settlement agreement with Woodside Energy, paying US$6,029,899 concerning the RSSD Project claim.
- FAR Limited has a contingent payment agreement with Woodside Energy, which could give a maximum value of US$55 million, based on oil price and production conditions.
- The contingent payment is linked to the Sangomar Project in Senegal, and the payment terminates on the earliest of 31 December 2027 or when US$55 million is reached.
- The company has no outstanding loans or unused financing facilities as of the end of the quarter.
- Aggregate payments to related parties and their associates during the quarter were US$49,000, mainly for Non-Executive Director remuneration.
- The company forecasts having sufficient cash for 55.20 quarters based on current available funding and expenditures.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
Call 1300 880 160
Start a chat
Schedule a call
